Arcutis Takes Over ZORYVE Promotion from Kowa in Strategic Shift
Event summary
- Arcutis and Kowa mutually terminated their promotion agreement for ZORYVE on January 23, 2026.
- Arcutis will now handle sales and promotion of ZORYVE in pediatric and primary care settings.
- The company expects to remain cash flow break-even with no impact on 2026 net product sales guidance.
- ZORYVE is indicated for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis across various age groups.
The big picture
Arcutis' decision to take over ZORYVE promotion from Kowa reflects a strategic pivot towards direct control of market expansion. This move aligns with broader industry trends where biopharmaceutical companies increasingly internalize commercial operations to optimize growth and profitability. The shift underscores Arcutis' confidence in scaling ZORYVE's reach across multiple inflammatory skin diseases, positioning it for long-term market leadership.
What we're watching
- Execution Risk
- How Arcutis will manage the transition of ZORYVE promotion in primary care and pediatric markets without disrupting growth.
- Market Penetration
- Whether Arcutis can drive adoption of ZORYVE in primary care through incremental investments while maintaining dermatology salesforce focus.
- Financial Impact
- The pace at which Arcutis scales its promotion efforts and the potential impact on 2026 financial performance.